Tanezumab
Phase 2Monoclonal antibody
PfizerTanezumab is used to treat moderate to severe chronic pain from osteoarthritis. It works by blocking a protein in the body that carries pain signals to the brain, helping reduce pain and improve movement.[1] Tanezumab is currently being investigated across 3 indications[3], with its most advanced program in Phase 2.[1]
Tanezumab is one of 3 biologic programs targeting Fever. It is currently in Phase 2.
3
Indications
30
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Schwannoma
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Tanezumab
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis13 trials
Show 10 more trials
Low back pain4 trials
Arthritis2 trials
Endometriosis1 trial
9 more indications
Medication1 trial
Interstitial Cystitis1 trial
Peripheral Neuropathy1 trial
Drug1 trial
Bone Metastasis1 trial
Prostatitis1 trial
Schwannoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tanezumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]